- Details
- This conversation with Alicia Morgans, MD, MPH, Petros Grivas, MD, PhD, highlights a post hoc analysis of the JAVELIN Bladder 100 trial which further characterizes the efficacy of avelumab first-line maintenance of time to end of next-line therapy. In JAVELIN Bladder 100, eligible patients had unresectable locally advanced or metastatic urothelial carcinoma without disease progression with 4 to 6...
|
- Details
- Christopher Wallis and Zachary Klaassen provide insights into the Cancer Treatment Reviews publication Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. In the context of metastatic urothelial carcinoma, avelumab has previously been assessed in a large phase 1b study, using avelumab as salvage therapy in t...
|
- Details
- Several Phase III trials have read out in the first-line treatment of metastatic urothelial cancer in the past few years. In a discussion with Ashish Kamat, Matthew Galsky discusses the expanse in clinical data in metastatic urothelial cancer shaping the treatment landscape. Guiding this conversation, Matthew Galsky focuses on 4 main take-home points and shares optimism in potential development to...
|
- Details
- In this conversation, Alicia Morgans, MD MPH, Neeraj Agarwal, MD, and Petros Grivas, MD, PhD discuss the clinical trial findings from the JAVELIN Bladder 100 trial and how-to treat with chemotherapy followed by avelumab maintenance. They highlight the importance of this to the treatment algorithm of metastatic urothelial carcinoma and highlight a recent publication in Cancer Treatment Reviews on a...
|
- Details
- Avelumab first-line maintenance therapy is approved in the United States for patients with advanced urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy based on significantly prolonged overall survival versus best supportive care alone. (median 21.4 months versus 14.3 months; HR 0.69, 95% CI 0.56-0.86) as reported in the phase III JAVELIN Bladder 100 trial...
|
- Details
- The analysis of the JAVELIN Bladder 100 trial, efficacy by duration or number of cycles of first-line chemotherapy presented at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) helped clinicians understand, the outcomes of avelumab from the JAVELIN 100 trial. The number of cycles (cycle every 3 weeks), of first-line chemotherapy. The optimal duration of firs...
|
- Details
- The anti-PD-L1 avelumab in urothelial carcinoma—A discussion with investigator Dr Andrea Apolo. The JAVELIN Solid Tumor phase 1, open-label, dose-escalation trial investigated avelumab, a human monoclonal anti-PD-L1 antibody (anti-PD-L1), in patients with selected tumor indications (eg, NSCLC, breast cancer, colorectal cancer). Pooled analysis of two JAVELIN cohorts that included patients with adv...
|
- Details
- A new first-line standard of care -- JAVELIN Bladder 100 Platinum-based chemotherapy is currently the standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by chemotherapy resistance. In this Journal Club, Christopher Wallis, MD, PhD, and Zachary Klaassen, MD, MSc review the JAVELIN Bladder 100 randomized, phase...
|
- Details
- The identification of predictive biomarkers for immunotherapy response is an area of intense research interest. In this conversation with Alicia Morgans, MD, MPH, Srikala Sridhar MD, MSc, FRCPC highlights her presentation from the European Society for Medical Oncology (ESMO) 2020 virtual meeting. At this meeting, Dr. Sridhar presented an assessment of potential biomarkers for response within the J...
|
- Details
- Cora Sternberg, MD, FACP, an investigator on the phase 3 JAVELIN Bladder 100 trial shares the study design, rationale, and key outcomes from the trial. The JAVELIN Bladder 100 trial is a phase 3 randomized study for maintenance avelumab therapy in patients who derived disease response or stabilization from first-line platinum-based chemotherapy for advanced urothelial cancer. In this conversation...
|